SCHEMBL4355239

SCHEMBL4355239

COCc1nc(O)cc(O)c1C(=O)OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.47
ACHE P22303 1/20 0.47
HPGD P15428 3/20 0.45
CA12 O43570 5/20 0.42
CA1 P00915 5/20 0.42
CA2 P00918 5/20 0.42
CA7 P43166 5/20 0.42
CA9 Q16790 5/20 0.42
CA14 Q9ULX7 5/20 0.42
POLB P06746 3/20 0.39
GAA P10253 3/20 0.39
RECQL P46063 1/20 0.38
GLO1 Q04760 1/20 0.38
NR1H2 P55055 1/20 0.38
NR1H3 Q13133 1/20 0.38
PDK2 Q15119 1/20 0.38
PDK4 Q16654 1/20 0.38
KDM4E B2RXH2 3/20 0.37
XDH P47989 2/20 0.37
LMNA P02545 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8549690 0.75 CYP3A4 (0.47) CYP3A4ACHEHPGDCA12CA1
SCHEMBL27910339 0.72 CYP3A4 (0.49) CYP3A4ACHEHPGDCA12CA1
SCHEMBL9430194 0.71 CYP3A4 (0.44) CYP3A4ACHEHPGDCA12CA1
SCHEMBL30063260 0.71 MAPK1 (0.45) CYP3A4ACHEHPGDPOLBGAA
SCHEMBL10352684 0.71 CYP3A4 (0.45) CYP3A4ACHEHPGDCA12CA1
SCHEMBL25210352 0.71 MAPK1 (0.45) CYP3A4ACHEHPGDPOLBGAA
SCHEMBL725269 0.70 CYP3A4 (0.77) CYP3A4ACHEHPGDCA12CA1
SCHEMBL29812443 0.70 POLB (0.42) CYP3A4ACHEHPGDPOLBNR1H2
SCHEMBL16624267 0.69 NPC1 (0.48) CA12CA1CA2CA7CA9
SCHEMBL6493747 0.67 CYP3A4 (0.79) CYP3A4ACHEHPGDCA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090286767-A1 SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES NEUROGEN CORPORATION (US) 2009-11-19 US disclosed
US-20090286767-A1 SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES NEUROGEN CORPORATION (US) 2009-11-19 US disclosed
US-20090286767-A1 SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES NEUROGEN CORPORATION (US) 2009-11-19 US disclosed
US-7488740-B2 Substituted quinolin-4-ylamine analogues NEUROGEN CORPORATION (US) 2009-02-10 US disclosed
US-7488740-B2 Substituted quinolin-4-ylamine analogues NEUROGEN CORPORATION (US) 2009-02-10 US disclosed
US-7488740-B2 Substituted quinolin-4-ylamine analogues NEUROGEN CORPORATION (US) 2009-02-10 US disclosed
EP-1644372-A2 SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES NEUROGEN CORPORATION (US) 2006-04-12 EP disclosed
US-20050070547-A1 Substituted quinolin-4-ylamine analogues NEUROGEN CORPORATION 2005-03-31 US disclosed
WO-2005007652-A2 SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES NEUROGEN CORPORATION (US) 2005-01-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286767-A1 SUBSTITUTED QUINOLIN-4-YLAMINE ANALOGUES PIGS, HRH4, GPR52 CYP3A4 1264/4885ACHE 1868/4885HPGD 1997/4885
US-20050070547-A1 Substituted quinolin-4-ylamine analogues PIGS, HRH4, GPR52 CYP3A4 1381/4885ACHE 1829/4885HPGD 2031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.